Targeting the PI3K/Akt/mTOR Axis by Apigenin for Cancer Prevention

被引:96
|
作者
Tong, Xin [1 ]
Pelling, Jill C.
机构
[1] Northwestern Univ, Dept Pathol, Chicago, IL 60611 USA
关键词
Akt; mTOR; apigenin; cancer; CELL-CYCLE ARREST; CHEMOPREVENTIVE BIOFLAVONOID APIGENIN; CYCLOOXYGENASE-2; COX-2; EXPRESSION; SIGNAL-TRANSDUCTION PATHWAYS; GLUTATHIONE-S-TRANSFERASE; HUMAN PANCREATIC-CANCER; CYTOCHROME-C RELEASE; FLAVONOID APIGENIN; DIETARY FLAVONOIDS; TUMOR-CELLS;
D O I
10.2174/18715206113139990119
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Natural products are important sources of anti-cancer lead molecules, and high dietary consumption of fruits and vegetables is associated with a reduced risk of certain cancers. Many efforts have been devoted to identifying and developing plant-derived dietary constituents as chemopreventive agents. Among them, apigenin, a naturally occurring flavonoid found in a variety of fruits and leafy vegetables, has been shown to possess remarkable anti-oxidant, anti-inflammatory and anti-carcinogenic properties. This review summarizes the anti-cancer and chemopreventive effects of apigenin at cellular and molecular levels, its chemical structure and properties, with focus on mechanism related to apigenin's inhibition of the PI3K/Akt/mTOR signaling pathways.
引用
收藏
页码:971 / 978
页数:8
相关论文
共 50 条
  • [31] The PI3K/AKT/MTOR signaling pathway: The role of PI3K and AKT inhibitors in breast cancer
    Huemer F.
    Bartsch R.
    Gnant M.
    Current Breast Cancer Reports, 2014, 6 (2) : 59 - 70
  • [32] PI3K/Akt/mTOR inhibitors in breast cancer
    Joycelyn JX Lee
    Kiley Loh
    Yoon-Sim Yap
    Cancer Biology & Medicine, 2015, (04) : 342 - 354
  • [33] PI3K/Akt/mTOR inhibitors in breast cancer
    Lee, Joycelyn J. X.
    Loh, Kiley
    Yap, Yoon-Sim
    CANCER BIOLOGY & MEDICINE, 2015, 12 (04) : 342 - 354
  • [34] PI3K/AKT/mTOR Inhibitors In Ovarian Cancer
    Mazzoletti, M.
    Broggini, M.
    CURRENT MEDICINAL CHEMISTRY, 2010, 17 (36) : 4433 - 4447
  • [35] PI3K/Akt/mTOR inhibitors in breast cancer
    Joycelyn JX Lee
    Kiley Loh
    Yoon-Sim Yap
    Cancer Biology & Medicine, 2015, 12 (04) : 342 - 354
  • [36] Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer
    Bitting, Rhonda L.
    Armstrong, Andrew J.
    ENDOCRINE-RELATED CANCER, 2013, 20 (03) : R83 - R99
  • [37] From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy
    Georgakis, Georgios V.
    Younes, Anas
    EXPERT REVIEW OF ANTICANCER THERAPY, 2006, 6 (01) : 131 - 140
  • [38] Strategic advancements in targeting the PI3K/AKT/mTOR pathway for Breast cancer therapy
    Garg, Pankaj
    Ramisetty, Sravani
    Nair, Meera
    Kulkarni, Prakash
    Horne, David
    Salgia, Ravi
    Singhal, Sharad S.
    BIOCHEMICAL PHARMACOLOGY, 2025, 236
  • [39] Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
    Qingfang Li
    Zhihui Li
    Ting Luo
    Huashan Shi
    Molecular Biomedicine, 3
  • [40] Targeting the PI3K/AKT/mTOR Pathway in Hormone-Positive Breast Cancer
    Sara E. Nunnery
    Ingrid A. Mayer
    Drugs, 2020, 80 : 1685 - 1697